Cenix and Instituto de Medicina Molecular, AstraZeneca and Cellectricon, Kreatech Biotechnology and Ambion, National Institute of Advanced Industrial Science and Technology in Tokyo

Jul 04, 2005

Premium

Cenix, IMM Develop RNAi Screen for Malaria; Seek Funding for Larger Assay

Researchers at the Instituto de Medicina Molecular in Lisbon, Portugal, and Cenix Bioscience hjave developed an RNAi screen for malaria genes that may lead to better anti-malarial therapeutics, IMM and Cenix said last week in a statement.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

Breaking News

The Scan

Helix Launches 'App Store'

Helix customers can purchase apps that interpret different aspects of their genome, Technology Review reports.

More CAR-T Therapies Sought

The New York Times reports that a number of companies and research institutes are pursuing gene therapies.

Telomeres of Spawning Salmon

Salmon with shorter telomeres survive to make the trip back to their river homes, New Scientist reports.

This Week in PLOS

In PLOS this week: vaginal microbiome composition, population patterns of Chagas-carrying Rhodnius ecuadoriensis, and more.

Main menu